DK1812015T3 - Methods for inhibition of nkt cells - Google Patents
Methods for inhibition of nkt cellsInfo
- Publication number
- DK1812015T3 DK1812015T3 DK05851383.9T DK05851383T DK1812015T3 DK 1812015 T3 DK1812015 T3 DK 1812015T3 DK 05851383 T DK05851383 T DK 05851383T DK 1812015 T3 DK1812015 T3 DK 1812015T3
- Authority
- DK
- Denmark
- Prior art keywords
- nkt cell
- treatment
- inhibition
- methods
- nkt cells
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 3
- 229930186217 Glycolipid Natural products 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
- 102000006306 Antigen Receptors Human genes 0.000 abstract 1
- 108010083359 Antigen Receptors Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62456804P | 2004-11-02 | 2004-11-02 | |
| US70654805P | 2005-08-08 | 2005-08-08 | |
| PCT/US2005/040182 WO2006060117A2 (en) | 2004-11-02 | 2005-11-02 | Methods for inhibition of nkt cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1812015T3 true DK1812015T3 (en) | 2013-01-02 |
Family
ID=36565493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05851383.9T DK1812015T3 (en) | 2004-11-02 | 2005-11-02 | Methods for inhibition of nkt cells |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7682614B2 (https=) |
| EP (1) | EP1812015B1 (https=) |
| JP (1) | JP4948418B2 (https=) |
| CN (1) | CN101031307B (https=) |
| AT (1) | ATE539757T1 (https=) |
| AU (1) | AU2005310247A1 (https=) |
| CA (1) | CA2584971C (https=) |
| DK (1) | DK1812015T3 (https=) |
| ES (1) | ES2378076T3 (https=) |
| PT (1) | PT1812015E (https=) |
| WO (1) | WO2006060117A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1372668B1 (en) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| WO2011149881A2 (en) * | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Methods for the treatment and prevention of inflammatory diseases |
| RU2603075C2 (ru) * | 2010-11-25 | 2016-11-20 | Имнейт Сарл | Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками |
| US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
| JP2015502340A (ja) * | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| EP2906576B1 (en) * | 2012-10-12 | 2019-09-11 | The Brigham and Women's Hospital, Inc. | Glycosphingolipids and methods of use thereof |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2013388034B2 (en) | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| JP7493449B2 (ja) | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| JPWO2023153527A1 (https=) * | 2022-02-14 | 2023-08-17 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| EP0751780B1 (en) | 1993-06-21 | 2003-09-03 | Brigham And Women's Hospital | Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| JP3495740B2 (ja) | 1997-04-10 | 2004-02-09 | 麒麟麦酒株式会社 | α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤 |
| EP1011719A1 (en) | 1997-09-12 | 2000-06-28 | Brigham & Women's Hospital | Synthetic antigens for cd1-restricted immune responses |
| TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| EP1095062B1 (en) | 1998-07-09 | 2006-09-13 | Brian J. Nickoloff | Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| US20010051156A1 (en) | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| US20020071842A1 (en) | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| EP1288291A4 (en) | 2000-06-06 | 2004-05-12 | Kirin Brewery | METHOD FOR REPLACING NATURAL KILLER T CELLS |
| JP5184732B2 (ja) * | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| JP3986957B2 (ja) | 2000-08-18 | 2007-10-03 | 三菱電機株式会社 | ランプ用トランス |
| DE10046658A1 (de) | 2000-09-20 | 2002-04-04 | Bosch Gmbh Robert | Induktiver Übertrager und ein Verfahren zu dessen Herstellung |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| IL140537A0 (en) | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
| EP1372668B1 (en) * | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US6662434B2 (en) | 2001-04-03 | 2003-12-16 | General Electric Company | Method and apparatus for magnetizing a permanent magnet |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| US20030064967A1 (en) | 2001-04-11 | 2003-04-03 | Jayraz Luchoomun | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters |
| US20020171538A1 (en) | 2001-05-15 | 2002-11-21 | Kuo-Hsin Su | Vehicle motion detector and control device arrangement |
| US20020171557A1 (en) | 2001-05-18 | 2002-11-21 | Wegener William E. | Security electronic system |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| US8084020B2 (en) | 2002-05-01 | 2011-12-27 | Beth Israel Deaconess Medical Center | Use of anti-CD1 antibodies for the modulation of immune responses |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| ES2365210T3 (es) | 2002-06-14 | 2011-09-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health | Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales. |
| US7368142B2 (en) | 2002-08-01 | 2008-05-06 | Renew Life Formulas, Inc. | Natural sweetener |
| WO2004019900A1 (en) | 2002-08-27 | 2004-03-11 | Societe Des Produits Nestle | Preventing or treating epithelial tissue damage or hair loss |
| AU2003277021A1 (en) | 2002-09-27 | 2004-04-19 | Biomira, Inc. | Glycosylceramide analogues |
| US20040171522A1 (en) | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20040235162A1 (en) | 2003-03-18 | 2004-11-25 | Kirin Beer Kabushiki Kaisha | Method of preparing immunoregulatory dendritic cells and the use thereof |
| US20050032210A1 (en) | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| WO2004084874A2 (en) | 2003-03-24 | 2004-10-07 | Brigham And Women's Hospital, Inc. | Mtp inhibitors for inhibiting inflammation |
| EP1653977A2 (en) | 2003-07-17 | 2006-05-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of disorders associated with natural killer t cells |
| EP1767216B1 (en) * | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
-
2005
- 2005-11-02 WO PCT/US2005/040182 patent/WO2006060117A2/en not_active Ceased
- 2005-11-02 EP EP05851383A patent/EP1812015B1/en not_active Expired - Lifetime
- 2005-11-02 ES ES05851383T patent/ES2378076T3/es not_active Expired - Lifetime
- 2005-11-02 JP JP2007539372A patent/JP4948418B2/ja not_active Expired - Fee Related
- 2005-11-02 US US11/266,033 patent/US7682614B2/en not_active Expired - Fee Related
- 2005-11-02 AU AU2005310247A patent/AU2005310247A1/en not_active Abandoned
- 2005-11-02 CN CN2005800330994A patent/CN101031307B/zh not_active Expired - Fee Related
- 2005-11-02 DK DK05851383.9T patent/DK1812015T3/da active
- 2005-11-02 CA CA2584971A patent/CA2584971C/en not_active Expired - Fee Related
- 2005-11-02 PT PT05851383T patent/PT1812015E/pt unknown
- 2005-11-02 AT AT05851383T patent/ATE539757T1/de active
-
2010
- 2010-02-01 US US12/697,882 patent/US8679499B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006060117A3 (en) | 2007-03-01 |
| JP2008518974A (ja) | 2008-06-05 |
| JP4948418B2 (ja) | 2012-06-06 |
| ES2378076T3 (es) | 2012-04-04 |
| CA2584971C (en) | 2013-08-06 |
| WO2006060117A2 (en) | 2006-06-08 |
| AU2005310247A1 (en) | 2006-06-08 |
| US7682614B2 (en) | 2010-03-23 |
| ATE539757T1 (de) | 2012-01-15 |
| CN101031307A (zh) | 2007-09-05 |
| CN101031307B (zh) | 2012-09-05 |
| US20100197613A1 (en) | 2010-08-05 |
| CA2584971A1 (en) | 2006-06-08 |
| EP1812015A2 (en) | 2007-08-01 |
| EP1812015A4 (en) | 2008-02-20 |
| EP1812015B1 (en) | 2012-01-04 |
| PT1812015E (pt) | 2012-02-20 |
| US20060116332A1 (en) | 2006-06-01 |
| US8679499B2 (en) | 2014-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1812015T3 (en) | Methods for inhibition of nkt cells | |
| Kaer | α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles | |
| Ip et al. | Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management | |
| Cripps et al. | MDSC in autoimmunity | |
| Fujio et al. | Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity | |
| Sun et al. | The ATP-P2X7 signaling axis is dispensable for obesity-associated inflammasome activation in adipose tissue | |
| WO2008137758A3 (en) | Amino acid lipids and uses thereof | |
| Jervis et al. | New CD1d agonists: synthesis and biological activity of 6 ″-triazole-substituted α-galactosyl ceramides | |
| Sharif et al. | Regulation of autoimmune disease by natural killer T cells | |
| UA117216C2 (uk) | Пухлиноасоційований пептид та його застосування | |
| BR112013026114A2 (pt) | composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas | |
| WO2009086504A3 (en) | Collagen formulations for improved skin care | |
| MX2009003305A (es) | Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso. | |
| AR064220A1 (es) | Formulacion liofilizada mab abeta | |
| MX2009002937A (es) | Metodo y sistema para infusion controlada de substancias terapeuticas. | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| WO2009075774A3 (en) | Glycosaminoglycan-coated particles and uses thereof | |
| KR101983566B1 (ko) | 피부 외용제 조성물 | |
| Guiard et al. | Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid govern T cell response | |
| MX2009002787A (es) | Composiciones y métodos para prevenir el cáncer con cupredoxinas. | |
| Chen et al. | Hydrogen treatment protects mice against chronic pancreatitis by restoring regulatory T cells loss | |
| Meijlink et al. | 6 ″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria | |
| Hogan et al. | Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide | |
| Pareek et al. | Melittin as a therapeutic agent for rheumatoid arthritis: mechanistic insights, advanced delivery systems, and future perspectives | |
| Yin et al. | Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting |